In addition, another study proposed a paradigm of four tumor immunophenotypes based on the tumor immune microenvironment, specifically PDL1 expression and tumor‐infiltrating lymphocytes (TILs): PDL1−/TIL−, PDL1+/TIL+, PDL1−/TIL+, and PDL1+/TIL−.[41] This paradigm considered PDL1+/TIL− tumors as resistant to anti‐PD1/PDL1 therapy because of low T cell infiltration. Here, PDCD1 is linked to neoplasm.